KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
26.79
0.00 (0.00%)
May 22, 2026, 4:00 PM EDT - Market closed
KalVista Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, KalVista Pharmaceuticals stock has a consensus rating of "Hold" and an average price target of $28.6. The average 1-year stock price forecast is 6.76% higher than the current stock price, while the lowest is $27 (+0.78%) and the highest is $35 (+30.65%).
Price Target: $28.6 (+6.76%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for KalVista Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 3 | 3 | 4 | 2 | 2 |
| Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 5 | 5 | 6 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $37 → $27 | Strong Buy → Hold | Downgrades | $37 → $27 | +0.78% | May 1, 2026 |
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 30, 2026 |
| Stifel | Stifel | Strong Buy Maintains $39 → $42 | Strong Buy | Maintains | $39 → $42 | +56.77% | Mar 26, 2026 |
| Citizens | Citizens | Buy Maintains $29 → $28 | Buy | Maintains | $29 → $28 | +4.52% | Mar 26, 2026 |
| Needham | Needham | Strong Buy Maintains $35 → $36 | Strong Buy | Maintains | $35 → $36 | +34.38% | Mar 25, 2026 |
Financial Forecast
Revenue This Year
208.68M
from 73.62M
Increased by 183.47%
Revenue Next Year
329.72M
from 208.68M
Increased by 58.00%
EPS This Year
-1.29
from -3.05
EPS Next Year
0.73
from -1.29
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 261.8M | 458.0M | ||||||
| Avg | 208.7M | 329.7M | ||||||
| Low | 178.7M | 228.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 255.6% | 119.5% | ||||||
| Avg | 183.5% | 58.0% | ||||||
| Low | 142.7% | 9.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.10 | 1.11 | ||||||
| Avg | -1.29 | 0.73 | ||||||
| Low | -1.67 | 0.28 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.